# A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India

> **NCT06086353** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 6 (actual)

## Conditions studied

- Transthyretin Amyloid Cardiomyopathy

## Interventions

- **DRUG:** Tafamidis

## Key facts

- **NCT ID:** NCT06086353
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-25
- **Primary completion:** 2025-06-06
- **Final completion:** 2025-06-06
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06086353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06086353, "A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06086353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*